[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bioavailability\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bioavailability":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100498780","phase-1-curcumin-and-retinal-study-100498780",false,"NCT05774704","Curcumin and Retinal Study","Curcumin and Retinal Amyloid-beta Pilot Study","Inclusion:\n\n* Both male and female, age 40 - 89 years.\n* Diagnosed with Aβ deposits in retina (peripheral superior quadrants)--to be confirmed after consent obtained. If there is documentation the potential participant has been diagnosed with Aβ deposits in retina within 6 months before the consent session, we will use this diagnosis\u002Fdocumentation for eligibility criteria. Otherwise, the ophthalmic exam will be repeated after consent is obtained for the study.\n* No pre-existing liver or kidney diseases by self-report.\n\nExclusion:\n\n* Patients with ocular diseases (macular degeneration, severe diabetes retinopathy)\n* Had used systemic antibiotics within 1 month prior to the start of the study intervention\n* Had taken any turmeric or curcumin products within 2 weeks prior to the start of the study intervention\n* Had a known allergy to black pepper\n* Women that are pregnant or breastfeeding",true,"ALL","40 Years","89 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance\u002Fcomposition of gut microbiota.",[29,30,31],"Bioavailability","Gut Microbiome","Safety","RECRUITING","2026-01-12",{"date":35,"type":36},"2026-01-13","ACTUAL",{"date":38,"type":36},"2023-08-21",{"date":40,"type":22},"2026-12-31",{"name":42,"class":43},"Texas Tech University Health Sciences Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100597798","bioavailability-of-ration-items-containing-tart-cherry-extract-100597798","NCT07063173","Bioavailability of Ration Items Containing Tart Cherry Extract","Tart Cherry","Inclusion Criteria:\n\n* Active duty military personnel and civilians will be invited to participate in the study if they:\n\n  * Are between the ages of 18 (or 17 for military personnel) and 39.\n  * Are willing to participate in all study procedures and comply with all study instruction.\n  * In good health as determined by OMSO (Office of Medical Support and Oversight).\n  * Supervisor approval for federal civilian employees and non-HRV active-duty military personnel stationed at NSSC\n\nExclusion Criteria:\n\n* • Unable to understand verbal or written instructions or testing materials in English.\n\n  * Have a bleeding disorder (e.g., von Willebrand Disease, hemophilia) or are being treated with medication that will impair blood clotting (for example, coumadin)\n  * Have a history of GI-related conditions that may impact macronutrient absorption (e.g., Crohn's disease, ulcerative colitis, Celiac's disease or gluten sensitivity, bariatric surgery or gastroparesis, short bowel, inflammatory bowel disease, etc…);\n  * Any use of antibiotics or antifungal, except topical antibiotics\u002Fantifungals within 3 months of study participation.\n  * Colonoscopy within 3 months of study participation.\n  * Regular (i.e., weekly or more frequent) use of over-the-counter medications (including antacids, laxatives, stool softeners, and antidiarrheals) unless approved by OMSO and study PI.\n  * Are habitually taking nonsteroidal anti-inflammatory drugs (e.g., Advil, aspirin), corticosteroids (e.g., prednisone) or immunosuppressants (e.g. Humira);\n  * Have an allergy or aversion (extreme dislike) to any of the test foods(e.g., cherry flavored beverages or bar). Allergy symptoms may include anaphylaxis, hives or eczema, tingling\u002Fitching in the mouth, dizziness or fainting, diarrhea, nausea or vomiting, swelling of the lips, face, tongue and throat).\n  * Have donated blood within the past 8 weeks of the first test session or plan to donate blood during the study.\n  * Are not willing to abstain from tobacco products and vigorous exercise for at least 24 hours\" before each trial and consume a low-polyphenol diet two days prior to each test session and on the day of the test session.","17 Years","39 Years",{"count":55,"type":22},15,[57],"NA","To determine how consuming food items containing shelf-stored tart cherry impacts your body's ability to absorb and use the compounds within tart cherry.",[29],[61,62,63,64],"military","tart cherry","muscle recovery","polyphenols","2025-12-19",{"date":67,"type":36},"2025-12-29",{"date":69,"type":36},"2024-06-14",{"date":71,"type":22},"2025-12-31",{"name":73,"class":74},"United States Army Research Institute of Environmental Medicine","FED",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100539674","bioavailability-of-aronia-melanocarpa-100539674","NCT06306911","Bioavailability of Aronia Melanocarpa","Evaluating Kinetics and Bioavailability of Aronia Melanocarpa Extract in Healthy Young and Older Adults","Inclusion Criteria:\n\n* BMI between 18-35 kg\u002Fm2\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n\nExclusion Criteria:\n\n* Smoking or smoking cessation \\\u003C 12 months\n* Severe medical conditions, including asthma, kidney failure, auto-inflammatory diseases, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, gastrointestinal disorders such as Crohn's disease, colitis\n* Use of dietary supplements or medication affecting the main outcomes of the study (e.g. affecting gut metabolism, blood pressure medication)\n* Use of an investigational product within another biomedical intervention trial within the previous month\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Known pregnancy or lactation\n* Known allergy to study product\n* Difficult venepuncture","18 Years","75 Years",{"count":85,"type":22},16,[57],"The main objective of this study is to study the bioavailability and kinetics of acute Aronia Melanocarpa supplementation in healthy young (18-35 years) and older adults (55-75 years) adults. During the test day, participants will ingest a drink consisting of Aronia Melanocarpa extract (AME). The bioavailability and kinetics of AME will be assessed via frequent blood sampling, urine collection, and faecal sampling, in which AME and metabolite profiles will be quantified.",[29,89],"Kinetics","2024-06-12",{"date":92,"type":36},"2024-06-13",{"date":94,"type":36},"2024-03-25",{"date":96,"type":22},"2024-08",{"name":98,"class":43},"Maastricht University Medical Center"]